BioCryst Pharmaceuticals

  www.biocryst.com
  www.biocryst.com

BioCryst Pharmaceuticals Reviews

2 Reviews
3.6
2 Reviews

Recommend to a friend
Approve of CEO
BioCryst Pharmaceuticals President, CEO, and Director Jon P. Stonehouse
Jon P. Stonehouse
1 Rating
  1.  

    Great employees, less confident about leadership

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Career Opportunities
    Current Employee - Anonymous Employee in Durham, NC
    Current Employee - Anonymous Employee in Durham, NC

    I have been working at BioCryst Pharmaceuticals

    Pros

    Talented, hardworking employees. Lots of opportunity to grow outside of comfort zone. Projects are interesting and meaningful. Global trials so not merely US centric.

    Cons

    Anxiety over the future. As a small biotech, there is no funding and therefore an uncertain future. No promotions available although you can get experince.

    Recommends
    No opinion of CEO

BioCryst Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.biocryst.com
Headquarters Durham, NC
Size 16 to 50 Employees
Founded Unknown
Type Company - Public (BCRX)
Industry Biotech & Pharmaceuticals
Revenue $10 to $25 million (USD) per year

BioCryst Pharmaceuticals is tackling the bad enzymes that spread disease. The firm creates small molecule compounds that inhibit enzymes associated with viral diseases, autoimmune conditions, and cancer. BioCryst's most advanced candidate is influenza inhibitor peramavir. It is being developed with funding from the Department of Health and Human Services. Its other main candidate is fodosine, an enzyme inhibitor that suppresses T-cells. It is being investigated as a treatment for T-cell cancers, including some lymphomas and leukemias, by preventing T-cells from wildly... More

Work at BioCryst Pharmaceuticals? Share Your Experiences

BioCryst Pharmaceuticals

 
Click to Rate
or